Note: see grey ribbon on the top of the blog, click on "Share this blog", easy to use (if and as you wish)
TwitterFacebookGoogle BuzzGoogle ReaderSunday, June 12, 2011
abstract: Randomized surgical training for medical students: resident versus peer-led teaching (trial and error)
Blogger's Note: tip - get it in writing who will be performing the surgery before the surgery; trial, error, adverse events and living WITH the failures = patients' lives; "low-threat" = system issue
Randomized surgical training for medical students: resident versus peer-led teaching
Scott C. Graziano MDRandomized surgical training for medical students: resident versus peer-led teaching
, a, 
Available online 16 March 2011.
Objective
Medical students spend significant portions of their time in the operating room, with many learning skills through trial and error. Peer-assisted learning is a useful teaching and learning method. Our hypothesis is that students will perform basic skills in the operating room environment more often when taught by their peers.
Study Design
Sixty third-year medical students participated in an operating room introduction course. Learners were randomized into 2 cohorts: 1 led by obstetrics and gynecology residents, 1 led by fourth-year medical students. Assessment was performed using an objective, structured clinical exercise.
Results
Peer-assisted learners performed more steps correctly during the objective exercise compared with resident-assisted learners (16.1 vs 14.4 of 22 total steps assessed, P < .01).
Conclusion
Peer-assisted learning may be a useful teaching method for simulation training. Third-year medical students may benefit from this low threat and informal environment.
abstract: Treating cervical cancer: Breast and Cervical Cancer Prevention and Treatment Act patients - access to care
abstract : Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations authors U.S./Canada
Review
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations
Ritu Salani MD, MBAa, , , Floor J. Backes MDa, Michael Fung Kee Fung MB, BSb, Christine H. Holschneider MDc, Lynn P. Parker MDd, Robert E. Bristow MD, MBAe and Barbara A. Goff MDf
Received 19 February 2011;
accepted 8 March 2011.
Available online 11 June 2011.
Although gynecologic cancers account for only 10% of all new cancer cases in women, these cancers account for 20% of all female cancer survivors. Improvements in cancer care have resulted in almost 10 million cancer survivors, and this number is expected to grow. Therefore, determining the most cost-effective clinical surveillance for detection of recurrence is critical. Unfortunately, there has been a paucity of research in what are the most cost-effective strategies for surveillance once patients have achieved a complete response. Currently, most recommendations are based on retrospective studies and expert opinion. Taking a thorough history, performing a thorough examination, and educating cancer survivors about concerning symptoms is the most effective method for the detection of most gynecologic cancer recurrences. There is very little evidence that routine cytologic procedures or imaging improves the ability to detect gynecologic cancer recurrence at a stage that will impact cure or response rates to salvage therapy. This article will review the most recent data on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy.
Key words: cervical cancer; cytology; endometrial cancer; gynecologic cancer; imaging; ovarian cancer; surveillance
abstract: Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication
Purpose: Anaphylactic reactions (ARs) have been frequently reported with taxanes. The authors' purpose was to summarize published case reports and describe ARs from taxanes reported to the Food and Drug Administration (FDA) with a focus on use of package insert-specified prophylactic premedications (PPMs).
Conclusions: Mortality was reported in more docetaxel ARs than paclitaxel. Documented use of PPMs did not significantly impact mortality from ARs with docetaxel, but was associated with significantly lower mortality from ARs with paclitaxel.
New lesions versus growth of existing disease: Does it impact prognosis? ASCO Meeting Abstract
Note: this study concerns the clinical criteria for evidence of progressive/new disease
Conclusions:
In 9,741 (patients), survival after development of new lesions as the sole reason for progression did not significantly differ from patients with other reasons of PD (progressive disease). These findings give further validation to the use of new lesions as a classifier of PD according to established criteria. (RECIST)
Background:
Clinical trials use established criteria (RECIST or WHO) to determine objective tumor behavior on therapy. Participants are labeled to have progressive disease (PD) and are taken off study if they meet specific parameters of increase in size of their known lesions, but can also be labeled as PD if they develop new lesions without meeting criteria for progression in known lesions. To determine whether there are outcome disparities among these patients, we explored survival differences by reason of progression among patients who developed PD on study using data from the phase III Intergroup trial N9741 which compared IFL, FOLFOX4, and IROX as first-line therapy in advanced colorectal cancer (Goldberg JCO 2004).
multinational study: Brivanib -oral- (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)-- ASCO Meeting Abstract
Background:
Brivanib (B) is an oral once daily selective dual inhibitor of FGF and VEGF signaling currently in phase III development for advanced hepatocellular carcinoma and colorectal cancer.
"Biomarker exploration with potential for enrichment continues; breast and ovarian cohorts have been added to the trial."
Long-Term Doxorubicin Linked to Secondary Oral Cancers
".......Four patients who received long-term PLD for advanced-stage ovarian cancer developed malignant and/or premalignant lesions of the tongue and/or oral cavity. Dr. Cannon points out that there were only about 16 patients who received PLD for an extended period of time, "so 4 out of 16 patients is quite high."
All 4 of the patients had received maintenance therapy with PLD for at least 3 years. Of this group, 3 women were subsequently diagnosed with squamous cell carcinoma (SCC) of the tongue and/or oral cavity, and 1 patient was diagnosed with sublingual mucosa high-grade dysplasia. All 3 cases of SCCs were negative for human papillomavirus.
Of note, said Dr. Cannon, was a patient who presented with 3 separate lesions of SCC of the oral cavity.
"I don't think this is a coincidence, that 4 of 16 patients receiving this treatment developed oral cancers," he said. "If this treatment for ovarian cancer becomes more popular, then this is something that should become known. Early dental screening would need to be initiated, and the treatment may need to be stopped after a certain time period."
It is relatively uncommon for ovarian cancer patients to receive PLD for this length of time.......cont'd
also: see chart
Canadian Medicine: End of the line for the gravy train? (pharma/AstraZeneca)
"Pharma giant AstraZeneca will no longer fund.....cont'd
webconference - Grey Literature - consumer's perspective section (free web conference)
Grey Lit 102: Advanced Search Strategies for Grey Literature
NEW: View the Grey Lit 102 archived recording and access the presentation slides here.Date: Thursday, April 7, 2011 12:00 p.m.-1:00 p.m. (EDT)
Course Level: 101
Faculty: Melissa Ratajeski, M.L.I.S., R.L.A.T., University of Pittsburgh; Ahlam Saleh, M.D., M.L.S., University of Pittsburgh
Duration: 60 min.
Overview: This free Web conference (the "consumer's" perspective) discussed the challenges inherent in conducting advanced searches for grey literature and presents tactics for overcoming these challenges. Participants in this session learned:
- Who are the major users of grey literature, and why?
- What are best practices for searching and incorporating grey literature evidence into larger research efforts?
- Is it possible to systematically review grey literature (why or why not)?
- Are there critical assumptions or search parameters that can target a search and efficiently find desired evidence?
Grey Literature in Public Health Web Conference Series 2011 | Open Medicine Blog
AcademyHealth is pleased to announce that the archived recordings for all three Web conferences in the Grey Literature Web Conference Series are now available on the AcademyHealth website.
Presentation slides are also available.
To access the archived recordings, visit the Grey Literature Web Conference Series page.
ASCO - the End Part II - posting by Dee
ASCO - the End Part II: "All the Focus on Research Advocates where asked to video a testimonial about their experience as a Focus on Research Advocate at ASCO. Below is my testimonial.
I am an ovarian cancer survivor and advocate. Being part of the Focus on Research program this year has been an honor.
The preparation offered prior to attending the conference was invaluable. Learning about biomarkers, drug development and clinical trial design has increased my understanding of cancer research. Interacting with the webinar lecturers, Drs Byers, Hong and Bemis helped to improve my communication skills and raised my confidence to discuss research topics with poster presenters and education session lecturers. Knowing the language and acronyms of cancer pathways, drugs and agents was an asset during the conference.
At ASCO the interaction with other advocates and hearing about their experiences has been both enjoyable and inspirational. I look forward to maintaining these relationships for years to come.
Another benefit of my attendance has ben an increased respect for cancer researchers and the challenges they face in both the US and internationally. I was thrilled to interact with a large number of international researchers at poster sessions and in the lecture hall. Learning about advances such as PARP inhibitors, monoclonal antibodies and other individualized medicine agents gives me hope for the future of cancer research.
I look forward to working with my dissemination partner. My goal is to share the exciting research developments I learned about this weekend in terms that are understandable by patients and caregivers.
Thank you to the Research Advocacy Network for the incredible opportunity.
Dee
Every Day is a Blessing!
Subscribe to:
Posts
(
Atom
)
Posts
